SparingVision Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 23
Employees
  • Latest Deal Type
  • Later Stage VC
  • Investors
  • 11

SparingVision General Information

Description

Developer of a medical therapy intended to treat inherited blinding retinal disease retinitis pigmentosa. The company's offerings include a drug candidate to treat retinitis pigmentosa, the most frequent inherited retinal degeneration which can progress to blindness and affects many patients worldwide, enabling doctors to help patients recover from retinal diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 5/7 avenue Percier
  • CS40230
  • 75008 Paris
  • France
+33 01 00 00 00 00

SparingVision Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SparingVision Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 01-Jan-2021 000.00 Completed Generating Revenue
6. Early Stage VC (Series A) 20-Oct-2020 000.00 000.00 Completed Generating Revenue
5. Accelerator/Incubator 09-Jul-2019 00.000 0000 Completed Startup
4. Early Stage VC 10-Dec-2017 00.000 000.00 00.00 Completed Startup
3. Grant 01-Jan-2017 00000 000.00 Completed Startup
2. Early Stage VC (Series A) 28-Jul-2016 $17.1M $17.1M 000.00 Completed Startup
1. Accelerator/Incubator Completed Startup
To view SparingVision’s complete valuation and funding history, request access »

SparingVision Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Shares 00,000 00.000000 0000.00 0000.00 00 0000.00 000
To view SparingVision’s complete cap table history, request access »

SparingVision Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a medical therapy intended to treat inherited blinding retinal disease retinitis pigmentosa. The company's
Drug Discovery
Paris, France
23 As of 2021
000.00
0000000000 0 000.00

00000

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conse
0000 000000000
Newport Beach, CA
00.000
0000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SparingVision Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
00000 Angel-Backed Newport Beach, CA 00.000 0000000000 00.000
You’re viewing 1 of 1 competitors. Get the full list »

SparingVision Executive Team (9)

Name Title Board Seat Contact Info
Stanislas Piot Chief Financial Officer
Myriam Marussig Ph.D Chief Operating Officer
Rajiv Gangurde Ph.D Chief Technology Officer
Florence Lorget Ph.D Chief Development Sciences Officer
Thierry Léveillard Ph.D Co-Founder & Scientific Advisor
You’re viewing 5 of 9 executive team members. Get the full list »

SparingVision Board Members (7)

Name Representing Role Since
Benjamin Yerxa Ph.D Self Board Member 000 0000
Jeanne Cunicelli Self Board Member 000 0000
Karen Wagner Ysios Capital Board Member 000 0000
Laurent Arthaud Bpifrance Board Member 000 0000
Owen Smith 4BIO Capital Partners Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

SparingVision Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SparingVision Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Advent France Biotechnology Venture Capital Minority 000 0000 000000 0
4BIO Capital Partners Venture Capital Minority 000 0000 000000 0
Jeito Venture Capital Minority 000 0000 000000 0
UPMC Enterprises Corporate Venture Capital Minority 000 0000 000000 0
Ysios Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

SparingVision Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 20-Apr-2021 000000000000000000 Drug Discovery 00000000 0000000
To view SparingVision’s complete acquisitions history, request access »